Welcome to our dedicated page for Dariohealth news (Ticker: DRIO), a resource for investors and traders seeking the latest updates and insights on Dariohealth stock.
DarioHealth Corp. (NASDAQ: DRIO) is a digital health company focused on multi-chronic condition management through a user-centric digital therapeutics platform, and its news flow reflects developments across technology, clinical evidence, commercial traction and corporate strategy. News items frequently describe how Dario’s platform and suite of solutions deliver personalized, dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.
Recent announcements have highlighted the launch of DarioIQ™, an artificial intelligence layer integrated into the Dario Health app. This AI capability, initially introduced for a cohort of hypertension members in a direct-to-consumer setting, is described as a clinically aligned, conversational layer that integrates behavioral insights, real-time biometric interpretation and personalized guidance while working alongside Dario’s human coaching framework. The company’s news coverage explains how DarioIQ™ is intended to enhance chronic condition management without replacing human-centered guidance.
DarioHealth’s news also emphasizes peer-reviewed clinical and economic evidence. Publications in JMIR Cardio and the Journal of Medical Internet Research (JMIR) have been featured in press releases, detailing studies of data-driven digital nudges for blood pressure management and analyses of healthcare utilization and medical costs among adults with type 2 diabetes using Dario’s platform compared to matched individuals receiving usual care. These articles are presented as supporting evidence for Dario’s ability to impact outcomes and healthcare burden.
Investors and observers following DRIO news will also see updates on employer and health plan adoption, including the signing of new employer clients and expansion of Dario’s commercial pipeline, as well as financing events such as private placements and strategic reviews initiated by the Board of Directors. Together, these news items provide context on how DarioHealth develops its technology, validates its approach through research and pursues growth with payers, employers and partners.
DarioHealth Corp. (Nasdaq: DRIO) announced a pivotal agreement to provide its digital therapeutics solution to eligible employees of a subsidiary of a Fortune 500 technology company. This marks Dario's first self-insured employer client via the partnership with Vitality Group. The program, focusing on diabetes and hypertension solutions, will start enrolling members in January 2021. DarioHealth emphasizes its personalized, adaptive healthcare approach, aiming to improve employee health outcomes and reduce care costs.
DarioHealth Corp. (Nasdaq: DRIO) announced a partnership with Presbyterian Medical Services to deliver its remote patient monitoring (RPM) solution starting January 1, 2021. This collaboration aims to enhance care for patients with chronic conditions like diabetes and hypertension. Following a rigorous evaluation process, Dario's AI-powered RPM was selected for its superior technology and ability to improve patient engagement and health outcomes. The financial details of the agreement were not disclosed.
DarioHealth Corp. (Nasdaq: DRIO) has secured a partnership with Presbyterian Medical Services to implement its remote patient monitoring (RPM) solution, effective January 1, 2021. This collaboration aims to enhance care for patients with chronic conditions like diabetes and hypertension. Following a competitive evaluation, Dario's RPM solution was chosen for its superior technology and user experience. Financial terms of the agreement were not disclosed, but the partnership highlights Dario's commitment to improving patient health outcomes, particularly during the COVID-19 pandemic.
DarioHealth Corp. (Nasdaq: DRIO) has secured a contract to provide its digital therapeutic solutions to eligible employees of a Fortune 500 technology company, starting January 1, 2021. This initiative aims to enhance the health management of chronic conditions like diabetes and hypertension. The contract is a significant milestone, showcasing Dario's strategic pivot towards the B2B2C market. The award highlights the competitive strength of Dario's digital care solution, which is already used by tens of thousands of consumers globally.
DarioHealth Corp. (NASDAQ: DRIO) presented a clinical study at the 20th Annual Diabetes Technology Society Meeting, highlighting significant improvements in diabetes management for adults aged 65 and older using its digital therapeutics platform. The study, involving 940 participants, showed a 13% reduction in average blood glucose levels over six months and a 38.1% drop in high blood glucose readings in subjects older than 65. Results indicated that outcomes for older adults were comparable or even better than those for younger participants, suggesting the platform's efficacy in managing chronic conditions.
DarioHealth Corp. (Nasdaq: DRIO) reported third-quarter 2020 revenues of $2.04 million, a 14.2% sequential increase. The company successfully penetrated the B2B2C market, establishing partnerships with Vitality Group and HMC Healthworks to expand its user base. Despite growth, gross profit fell by 37% to $549,000, and operating losses rose to $6.6 million, a 136% increase year-over-year. Cash reserves stand at $37 million, the highest in company history, supporting further investments. However, total operating expenses increased by 94.7%, primarily from marketing and compensation costs.
DarioHealth Corp. (Nasdaq: DRIO) announced it will release its financial results for Q3 2020, ending September 30, on November 12, 2020. A conference call is scheduled for 9:00 AM Eastern Time to discuss the results, featuring key executives including CEO Erez Raphael. The call will allow investors to gain insights into the company's financial performance and future outlook within the digital therapeutics market. A replay of the call will be accessible for two weeks following the event.
DarioHealth Corp. (Nasdaq: DRIO) announced its digital therapeutics solutions will be integrated into Vitality Group's new Gateway Flex offering. This partnership aims to provide employers with personalized healthcare solutions, enhancing employee engagement and cost-effectiveness. Dario's President, Rick Anderson, expressed confidence that this inclusion validates their digital therapeutic solutions. The partnership with Vitality Group, initiated in March 2020, aims to accelerate Dario's reach within the self-insured employer market, catering to the increasing demand for tailored health applications.
DarioHealth Corp. (Nasdaq: DRIO) has partnered with HMC HealthWorks to integrate its digital therapeutics solutions into HMC's care management programs. This collaboration enables HMC to offer DarioHealth's platform both independently and as part of its comprehensive health management services. DarioHealth aims to enhance chronic condition management for patients, validating its transition to a digital therapeutics provider. The partnership is expected to expand DarioHealth's distribution and build a client pipeline within HMC's extensive customer base.
DarioHealth Corp. (Nasdaq: DRIO) has appointed Eric Milledge as Chairman of its newly-formed Scientific Advisory Board (SAB). With over 34 years at Johnson & Johnson, Milledge brings extensive experience in pharmaceuticals and medical devices. His leadership roles included overseeing successful product launches and managing strategic hospital contracts. At DarioHealth, he will guide the SAB in enhancing digital therapeutics for chronic conditions, focusing on creating data supporting Dario's technology platform and expanding its offerings, like the integration of continuous glucose monitors.